NovoTTF: Where to go from here?

Neuro-Oncology

Volumn 19, Issue 5, 2017, Pages 605-608

  Cloughesy, Timothy F ^a   Lassman, Andrew B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; CANCER THERAPY; CHEMORADIOTHERAPY; DNA METHYLATION; GLIOBLASTOMA; HUMAN; MEDICAL DEVICE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; TUMOR TREATMENT FIELD DEVICE; TUMOR TREATMENT FIELD THERAPY; BRAIN TUMOR; DEVICES; ELECTROTHERAPY; PROCEDURES;

BRAIN NEOPLASMS; ELECTRIC STIMULATION THERAPY; EQUIPMENT AND SUPPLIES; GLIOBLASTOMA; HUMANS;

EID: 85019100348     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox014     Document Type: Review

References (10)

1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.
2. Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X. The cost-effectiveness of tumor-treating felds therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016;18(8):1129-1136.
3. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating felds plus temozolomide vs temozolomide alone for glioblas-toma: a randomized clinical trial. JAMA. 2015;314(23):2535-2543.
4. Grady D. Electrical scalp device can slow progression of deadly brain tumors. The New York Times. November 15, 2014, A26.
5. Stupp R, Idbaih A, Steinberg DM, et al. LTBK-01: prospective, multi-center phase III trial of tumor treating felds together with temozolomide compared to temozolomide alone in patients with newly diagnosed glio-blastoma. Neuro Oncol. 2016; 18(suppl 6):i1.
6. Neighbors LB, Portnow J, Ammirati M, et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: central nervous system cancers (Version 1.2016). 2016; https://www.nccn.org/professionals/physician-gls/pdf/cns.pdf. Accessed January 9, 2017.
7. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333-343.
8. Stupp R, Hegi ME, Mason W P, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
9. Hegi ME, Stupp R. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma? Neuro Oncol. 2015;17(11):1425-1427.
10. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006; 148(3):269-275; discussion 275.